HUTCHMED (China) Limited (AIM:HCM)

Market Cap	1.88B +0.3%
Revenue (ttm)	439.54M -1.4%
Net Income	340.78M
EPS	0.39
Shares Out	859.52M
PE Ratio	5.66
Forward PE	12.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,283
Average Volume	51,248
Open	209.00
Previous Close	219.00
Day's Range	209.00 - 220.00
52-Week Range	185.50 - 292.00
Beta	0.52
RSI	51.29
Earnings Date	Mar 5, 2026

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,780
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HCM

Financial Performance

In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.

Financial numbers in USD